A second United States citizen has tested positive for Bundibugyo virus, a type of Ebola, while working as a humanitarian worker in the Democratic Republic of the Congo. The CDC and the European Centre for Disease Prevention and Control confirmed the case on July 10, 2026. The patient was medically evacuated from DRC to a university hospital in Frankfurt, Germany, on July 13 and is reported to be in stable condition.
No Bundibugyo virus cases have been confirmed on U.S. soil. The overall risk to the American public remains low, according to the CDC. But the outbreak has grown into the third-largest Ebola epidemic on record, and with two Americans now evacuated and the World Health Organization warning of significant undercounting in the field, the situation warrants close attention from anyone involved in international travel, aid work, or global health.
Why This Matters
Most Americans face minimal direct risk from the Bundibugyo outbreak. The virus does not spread through the air and requires direct contact with the blood, body fluids, or secretions of someone who is sick or has died from the disease. That is why healthcare workers, funeral workers, and family members who provide direct care to ill patients face the greatest danger.
What elevates the domestic relevance is the pattern of international spread. In addition to the two U.S. cases medically evacuated to Germany, France reported an imported Bundibugyo case on June 24, 2026. The WHO declared this outbreak a Public Health Emergency of International Concern on May 17, 2026, a designation reserved for events of serious international public health significance. Anyone traveling to DRC or Uganda for humanitarian, medical, or aid purposes faces meaningfully elevated personal risk and should consult CDC travel guidance before departure.
What We Know So Far
The Bundibugyo outbreak was first declared on May 15, 2026, by the DRC Ministry of Public Health after laboratory analysis confirmed Bundibugyo ebolavirus in Mongbwalu Health Zone, Ituri Province. By July 13, the outbreak had grown to approximately 1,926 confirmed cases and 702 deaths, according to official DRC figures reported to WHO. That figure makes this the third-largest Ebola epidemic on record after the 2014-2016 West Africa outbreak and the 2018-2020 DRC outbreak.
The WHO has warned that official figures likely represent a significant undercount. With limited laboratory access, ongoing conflict in eastern DRC, and disrupted health infrastructure, many cases go undetected. The WHO's emergencies chief has stated that most cases are arising from unknown transmission chains, a sign that contact tracing has not kept pace with the outbreak's spread.
On July 10, 2026, the CDC confirmed that a U.S. citizen working for a humanitarian organization in DRC had tested positive for Bundibugyo virus. This was the second confirmed case in a U.S. citizen; an earlier American humanitarian worker was medically evacuated to Germany in May 2026. The July patient was evacuated on July 13 and remains in stable condition at a Frankfurt university hospital.
Where the Risk Is Highest
The outbreak has expanded across five provinces in northeastern DRC, with the heaviest concentration in Ituri Province, where it originated. North Kivu, Haut-Uele, Tshopo, and South Kivu provinces have also reported cases. All confirmed cases in Uganda so far have been diagnosed in Kampala and are connected to travel from the DRC, with no community spread in Uganda reported.
The risk for people in the United States or other countries remains very low. Unlike airborne illnesses such as measles or COVID-19, Bundibugyo virus requires close physical contact with a sick individual or their bodily fluids. It does not survive long outside a human host.
The highest-risk populations globally include healthcare workers in DRC treating confirmed or suspected patients, family members providing direct care to ill relatives, humanitarian and aid workers operating in affected health zones, and laboratory personnel handling specimens from confirmed cases.
The CDC currently maintains a Level 2 travel notice for DRC (Practice Enhanced Precautions) and a Level 1 notice for Uganda (Practice Usual Precautions).
What Doctors and Experts Say
Unlike the more commonly discussed Ebola virus disease, Bundibugyo virus disease has no licensed vaccine and no approved specific treatment. The WHO's guidance states that response strategies rely on "comprehensive public health measures, including supportive care, early case detection, stringent infection prevention and control protocols, rigorous contact tracing, safe burial practices, and deep community engagement."
Supportive care with intravenous fluids, oxygen, and treatment of secondary infections remains the primary clinical approach. Researchers at the University of Oxford have launched the first Phase I clinical trial of a vaccine specifically targeting Bundibugyo ebolavirus under the BD-Ebov program. Researchers in DRC have also begun a randomized trial evaluating remdesivir and the monoclonal antibody MBP134 as experimental Bundibugyo treatments.
The ECDC assessed the risk for people living in the European Union as "very low," citing the same transmission requirements that limit risk for Americans.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Outbreak type: Active Ebola disease outbreak caused by Bundibugyo virus (BDBV), a distinct Orthoebolavirus species
- Confirmed cases (July 13, 2026): Approximately 1,926 with 702 deaths, per DRC official figures
- WHO classification: Public Health Emergency of International Concern (PHEIC), declared May 17, 2026
- Licensed vaccine: None for Bundibugyo virus
- Licensed treatment: None specific; supportive care only
- U.S. domestic risk: Low; no confirmed U.S.-soil cases
- What it does not show: Whether experimental vaccine or treatment trials will alter the outbreak trajectory in time to affect the current case curve
- What readers should know: Travel to affected DRC provinces carries real risk; humanitarian workers should consult the CDC travel health notice and their organization's medical advisory protocols before deployment
Who Faces the Greatest Risk?
In the United States, the population most directly at risk is narrow but real: U.S. citizens planning humanitarian, medical, or aid travel to DRC or Uganda; healthcare workers who might receive a medically evacuated patient in a U.S. biocontainment unit; and travelers transiting through affected regions.
For everyone else in the U.S., the direct personal risk is very low. The concern is primarily humanitarian: more than 700 people have died in a resource-constrained region where conflict, food insecurity, and health system degradation are compounding an already severe outbreak response.
Symptoms and Warning Signs to Watch For
Anyone who has traveled to DRC or Uganda in the past 21 days and develops the following symptoms should immediately isolate and contact a health care provider:
- Sudden fever
- Severe headache
- Muscle pain and weakness
- Fatigue
- Nausea, vomiting, or diarrhea
- Stomach pain
- Unexplained bleeding or bruising
- Nosebleeds, vomiting blood, or blood in stool in more advanced cases
Returning travelers with any of these symptoms should call ahead before arriving at a clinic or emergency room, identify themselves as recent travelers to DRC or Uganda, and follow instructions from health care staff before entering the facility.
What You Can Do Now
- If you are planning to travel to DRC, Uganda, or surrounding regions, review the CDC travel health notices for DRC (Level 2) and Uganda (Level 1).
- Humanitarian and aid organizations deploying staff to DRC should consult current WHO and CDC guidance and ensure workers have clear protocols for reporting fever or symptoms.
- If you have recently returned from DRC or Uganda and develop fever or other Ebola-consistent symptoms, call your health care provider before visiting in person and tell them about your travel history.
- Do not rely on unverified social media reports about the outbreak's status. Case counts and geographic spread are updated regularly at the WHO and CDC websites.
- For returning travelers who are symptom-free, no quarantine is required, but self-monitoring for 21 days is recommended by the CDC.
Cost and Access: What Patients Should Know
No FDA-approved Bundibugyo-specific treatment is currently available. For anyone medically evacuated to the United States, care would be provided at one of the federally designated biocontainment units at academic medical centers equipped to handle high-consequence pathogens. For travelers seeking pre-deployment guidance, the CDC's Travelers' Health website provides updated destination-specific recommendations at no cost.
What Happens Next
The WHO and CDC are expected to continue weekly situation updates as the outbreak evolves. Experimental vaccine and treatment trials in DRC are ongoing, and results from early-phase safety trials could inform response strategy later this year. The WHO's IHR Emergency Committee is expected to reconvene periodically to assess whether the PHEIC designation should be maintained or updated. MedicalDaily will report on significant changes in case counts, geographic spread, or guidance for Americans.
The Bottom Line
The Bundibugyo Ebola outbreak in DRC is the third-largest on record, and two American humanitarian workers have now tested positive, with both being medically evacuated to Germany in stable condition. For the vast majority of Americans, direct risk remains very low. But for anyone involved in international aid work, global health deployment, or travel to Central Africa, this outbreak requires serious pre-departure planning, up-to-date awareness of travel notices, and a clear protocol for symptom monitoring after return.
